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Barley-ß-glucans reduce 
systemic inflammation, renal 
injury and aortic calcification 
through ADAM17 and neutral-
sphingomyelinase2 inhibition
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Grattoni1, Petya Valcheva1, Catalina Ulloa3, Javier Rodríguez-Carrio2,4, Anna cardús1,5, 
Covadonga Quirós-Caso2, Laura Martínez-Arias2, Carlos Martínez-Salgado6, 
María José Motilva7, Carmen Rodriguez-Suarez5, Jorge B. Cannata-Andía2,8,10 & 
Adriana S. Dusso1,2,10*
In chronic kidney disease (CKD), hyperphosphatemia-induced inflammation aggravates vascular 
calcification (VC) by increasing vascular smooth muscle cell (VSMC) osteogenic differentiation, 
ADAM17-induced renal and vascular injury, and TNFα-induction of neutral-sphingomyelinase2 
(nSMase2) to release pro-calcifying exosomes. This study examined anti-inflammatory β-glucans 
efficacy at attenuating systemic inflammation in health, and renal and vascular injury favoring VC in 
hyperphosphatemic CKD. In healthy adults, dietary barley β-glucans (Bβglucans) reduced leukocyte 
superoxide production, inflammatory ADAM17, TNFα, nSMase2, and pro-aging/pro-inflammatory 
STING (Stimulator of interferon genes) gene expression without decreasing circulating inflammatory 
cytokines, except for γ-interferon. In hyperphosphatemic rat CKD, dietary Bβglucans reduced renal 
and aortic ADAM17-driven inflammation attenuating CKD-progression (higher GFR and lower serum 
creatinine, proteinuria, kidney inflammatory infiltration and nSMase2), and TNFα-driven increases in 
aortic nSMase2 and calcium deposition without improving mineral homeostasis. In VSMC, Bβglucans 
prevented LPS- or uremic serum-induced rapid increases in ADAM17, TNFα and nSMase2, and 
reduced the 13-fold higher calcium deposition induced by prolonged calcifying conditions by inhibiting 
osteogenic differentiation and increases in nSMase2 through Dectin1-independent actions involving 
Bβglucans internalization. Thus, dietary Bβglucans inhibit leukocyte superoxide production and 
leukocyte, renal and aortic ADAM17- and nSMase2 gene expression attenuating systemic inflammation 
in health, and renal injury and aortic calcification despite hyperphosphatemia in CKD.
In Chronic Kidney Disease (CKD), the development of hyperphosphatemia increases the risk of vascular calci-
fication (VC) and cardiovascular mortality1. Elevations in serum phosphate (P), even to levels below the upper 
normal limit, increase the propensity for VC indirectly by worsening secondary hyperparathyroidism (SHPT) 
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and bone de-mineralization2 and also directly, by inducing the osteogenic differentiation of vascular smooth 
muscle cells (VSMC)3.
Hyperphosphatemia also increases systemic inflammation4,5 and consequently, oxidative-stress-driven 
multi-organ injury6,7 worsening CKD-induced renal and vascular damage predisposing to VC and high mortality 
rates1,3. Part of the renal and vascular deleterious effects of oxidative stress involves the induction of two critical 
enzymes: ADAM17 (A Disintegrin And Metalloproteinase, also called TACE for Tumor necrosis factor Alpha 
Converting Enzyme)8,9 and neutral sphyngomyelinase 2 (nSMase2)10. Specifically, renal ADAM17 expression 
increases in CKD of all etiologies11 aggravating renal damage12 and systemic inflammation, the latter by releasing 
soluble TNFα to the circulation9. In turn, TNFα induces its own gene expression13, and also the ADAM17 gene14, 
generating a vicious ADAM17/TNFα feed-forward inflammatory loop that worsens multi-organ injury9. In fact, 
in the severe inflammation of LPS-induced endotoxic shock in mice, exclusive ablation of the ADAM17 gene in 
mouse myeloid cells is sufficient to markedly reduce mortality rates15.
In the vasculature, TNFα increases local inflammation aggravating VSMC osteogenic differentiation7, and 
also, nSMase2 gene expression and activity16, an essential determinant of aging-induced inflammation, ath-
erosclerosis and VC10,16,17. In fact, nSMase2 gene ablation or pharmacological inhibition of nSMase2 activity 
markedly reduces age-enhanced inflammation in health10, the higher propensity for atherosclerotic lesions in 
the ApoE−/− mouse17 and, more significantly for CKD, the release of exosomes initiating medial calcification16.
Based upon current therapeutic limitations to lower hyperphosphatemia in CKD18, and considering that orally 
administered yeast ß-glucans efficaciously reduce multi-organ injury and mortality rates in LPS-challenged rats,19 
this study was designed to examine whether an anti-inflammatory strategy with β-glucans could effectively atten-
uate systemic inflammation in health, including the mediator of early pro-senescent/pro-inflammatory interferon 
like responses, activated by the cGAS/STING pathway of cytosolic dsDNA recognition20 and also, renal and vas-
cular injury predisposing to VC in a rat model of hyperphosphatemic rat CKD.
To test this hypothesis, among the multiple natural sources for β-glucans, we chose barley β-glucans 
(Bβglucans), based upon the safety of the FDA recommended daily intake of 3 to 5 g for their cholesterol21,22 low-
ering capacity. Specifically, we evaluated the efficacy of dietary Bβglucans to reduce: (a) Systemic inflammation 
in healthy adults with normal renal function; (b) Renal and aortic inflammation and the propensity for CKD 
progression and aortic calcium deposition in a rat model of hyperphosphatemic CKD, and (c) The contribution 
of Bβglucans regulation of ADAM17 and nSMase2 expression to their anti-inflammatory/anti-calcifying actions 
in vivo and in vitro in VSMC.
Results
Human study. Systemic anti-inflammatory actions by dietary BßGlucans. The daily intake of 3 g 
of BßGlucans, as barley bread by 10 individuals with normal renal function during 4 weeks, decreased circulating 
leukocyte mitochondrial superoxide production by 50% in one week (Supplementary Fig. 1).
In the 5 volunteers that completed the 3 g daily intake of BßGlucans for one month, the 50% inhibition of leu-
kocyte superoxide production in the first week remained up to the end (week 4) (Fig. 1a). Furthermore, dietary 
BßGlucans also decreased leukocyte median mRNA levels of three recognized inflammatory markers: ADAM17 
(80% at week 1 and 94% at week 4; p < 0.05) (Fig. 1b), TNFα (64% (not significant) at week 1 and 80% at week 4, 
p < 0.05) (Fig. 1c) and nSMase2 (58% at week 1 and 77% at week 4; p < 0.05) (Fig. 1d). These BßGlucans actions 
in circulating leukocytes after 1 or 4 weeks of a daily intake occurred despite no increases in serum levels either 
of β-glucans or in markers of bone and mineral homeostasis (calcium, phosphate, PTH, soluble klotho) or of 
systemic inflammation (C reactive protein and pro-inflammatory cytokines, except for a significant reduction of 
γ-interferon by week 4) (Table 1).
Dietary BßGlucans-driven reductions in serum γ-interferon levels were paralleled by significant decreases in 
leukocyte STING mRNA (r = 0.54; p = 0.05; Fig. 1f). In fact, leukocyte STING mRNA levels decreased by 90% 
(p < 0.01) by week 4 (Fig. 1e) of dietary BßGlucans intake. Furthermore, this reduction strongly correlated with 
that of leukocyte nSMase2 gene expression (r = 0.80; p = 0.001; Fig. 1g).
Animal study. Renal anti-inflammatory actions by dietary BßGlucans. The administration of the 
high P diet containing BßGlucans to uremic rats had no effect on daily food consumption (20 g/day) or body 
weights (CKD: 234 ± 13 g to 248 ± 23 g; n = 13; CKD + Bßglucans: 237 ± 9 g to 255 ± 18 g; n = 13). Furthermore, 
despite undetectable serum (1,3)-ß-D-glucan levels, the CKD + Bßglucans group showed better renal function 
compared to the CKD group (lower serum creatinine, BUN, proteinuria and higher renal klotho) (Table 2), as 
well as reduced inflammatory markers (lower renal inflammatory cell infiltration (Table 2), ADAM17 protein 
and mRNA (Fig. 2a,b) and nSMase2 mRNA) (Fig. 2c). Serum and urinary TNFα levels were undetectable in both 
dietary groups.
Regarding bone and mineral parameters, there were no significant differences in serum calcium, phosphate, 
PTH, 25-hydroxyvitamin D, FGF23 and bone alkaline phosphatase between groups (Table 3). The higher renal 
klotho found in the CKD + Bßglucans group (Table 2) did not result in increases in 24 hours phosphaturia 
(Table 3).
Animal study. Vascular anti-inflammatory actions by BßGlucans. The uremic rats fed the high P 
diet with Bßglucans had significantly lower median aortic ADAM17 protein (47%) (Fig. 3a,b), ADAM17 and 
TNFα mRNA levels (80%) (Fig. 3c) and nSMase2 mRNA levels (65%) and activity (55%) compared with the 
CKD group (Fig. 3d). Furthermore, in the aortas of these uremic rats, TNFα mRNA levels correlated directly 
with ADAM17 mRNA (r = 0.81; p < 0.001) and also with nSMase2 mRNA levels and activity (r = 0.89; p < 0.001 
and r = 0.81; p < 0.01, respectively).
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Animal study. Vascular anti-calcifying actions by dietary BßGlucans. In the CKD group, 36% of 
the aortas were Von Kossa positive while all aortas from the CKD + Bßglucans group stained negatively (Fig. 4a). 
Furthermore, median aortic total calcium was 8 times lower in the CKD + Bßglucans group (7.5 µg Ca/mg 
Figure 1. Dietary Bßglucans inhibit mitochondrial superoxide production, ADAM17, TNFα, nSMase2 and 
STING gene expression in circulating leukocytes from healthy adults. Box plot analyses of changes in baseline 
superoxide production (a), ADAM17 (b), TNFα (c), nSMase2 (d) and STING (e) mRNA levels (each shape 
represents one individual) in peripheral blood monocytes from 5 healthy adults ingesting 3 g of Bßglucans daily, 
as slices of barley bread, during 4 weeks. *p < 0.05 and **p < 0.01 vs. Baseline, #p < 0.05 vs. 1week. Correlation 
between leukocyte STING mRNA and serum γ-interferon levels (f) and between leukocyte STING and 
nSMase2 mRNA levels (g). Each shape represent baseline (●), one week (■) and 4 weeks (▲) values.
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protein) compared to uremic controls (CKD group: 60 µg Ca/mg protein) (Fig. 4b). Despite the higher Ca depo-
sition found in the CKD group, there were minor changes in median aortic mRNA levels of osteogenic differen-
tiation markers (reductions in α-actin and increases in Runx2 and Osterix) compared to the CKD + Bßglucans 
group, which did not reach statistical significance (Table 4). Instead, total aortic calcium content strongly corre-
lated with increases in nSMase2 activity (r = 0.60; p < 0.01).
In vitro studies. Direct anti-inflammatory/anti-calcifying actions by BßGlucans in VSMC. 
Protocol 1 searched for an effective anti-inflammatory dose of BßGlucans extracts in the murine monocyte cell 
line Raw 264.7, exposed to 5 µg/mL of E. Coli LPS for 16 hours to reproduce severe systemic inflammatory stimuli.
Exposure to LPS increased mitochondrial superoxide production by 2-fold (Supplementary Fig. 1). A dose of 
100 µg/mL of commercial BßGlucans extracts was necessary to fully prevent LPS-induced superoxide production. 
In unstimulated monocytes, the 100 µg/mL dose of BßGlucans extracts elicited anti-inflammatory actions as it 
reduced baseline monocyte superoxide production by 50% (Supplementary Fig. 1).
Protocol 2 examined the impact of LPS-driven inflammation on VSMC phenotype. In A7r5 cells, the exposure 
to 100 µg of BßGlucans/mL for 16 hours had no effect on basal nSMase2, TNFα or ADAM17 gene expression 
(Fig. 5a–c). A7r5 exposure to LPS for 16 hours sufficed to significantly increase nSMase2, TNFα and ADAM17 
gene expression (Fig. 5a–c) above the levels in unstimulated controls. Furthermore, the combination of the 
same dose of LPS with 100 µg/mL Bßglucans fully prevented LPS-driven increases in nSMase2 gene expression 
maintaining nSMase2 mRNA at the levels of the control group, failed to counteract LPS-induction of TNFα and 
decreased LPS-induced ADAM17 gene expression only marginally (Fig. 5a–c).
Regarding osteogenic differentiation, A7r5 exposure to 100 µg of BßGlucans/mL for 16 hours had no effect on 
basal mRNA levels of α-actin, Runx2 or osterix. Instead, while LPS exposure significantly decreased A7r5 levels 
of α-actin and increased Runx2 and Osterix gene expression compared to those in the control group (Fig. 5d–f), 
the combination of LPS with 100 µg/mL Bßglucans attenuated the stimulatory effect of LPS maintaining the oste-
ogenic differentiation markers at levels similar to those in the control group (Fig. 5d–f).
Baseline 1 week BßGlucans 4 weeks BßGlucans
(n = 5) (n = 5) (n = 5)
Serum ßglucans
   (1,3)-β-D-glucan (pg/mL) Undetectable Undetectable Undetectable
Renal function
   Creatinine (mg/dL) 0.86 ± 0.10 0.89 ± 0.12 0.90 ± 0.16
   Urea (mg/dL) 23.9 [21.9–52.3] 26.3 [25.6–39.1] 26.8 [24.2–29.9]
   Albumin (g/L) 46.02 ± 2.57 45.3 ± 1.48 44.46 ± 2.15
Mineral homeostasis
   Calcium (mmol/L) 2.37 ± 0.08 2.32 ± 0.07 2.32 ± 0.05
   Phosphorus (mmol/L) 1.29 ± 0.18 1.18 ± 0.16 1.14 ± 0.23
   PTH (pg/dL) 56.00 [36.40–58.40] 51.70 [33.00–55.90] 31.9 [30.9–43.2]
   Klotho (pg/mL) 925.33 [809.83–1,003.17] 873.17[749.83–1,001.50] 868.00 [819.83–1,010.83]
Inflammation
   C Reactive Protein (mg/dL) 0.11 [0.04–0.22] 0.05 [0.04–0.10] 0.10 [0.04–0.13]
   IL-2 (pg/mL) 1.37 ± 0.21 1.54 ± 0.26 1.47 ± 0.48
   IL-6 (pg/mL) 4.31 ± 0.50 2.91 ± 1.52 3.55 ± 1.05
   TNFα (pg/mL) 5.18 ± 3.15 5.20 ± 4.00 3.86 ± 1.47
   γ-INFγ (pg/mL) 7.05 ± 1.28 6.31 ± 2.28 3.71 ± 1.73*
   VCAM-1 (ng/mL) 2,180.68 ± 117.97 2,130.27 ± 34.16 2,246.75 ± 139.80
Table 1. Serum biochemistries in healthy volunteers. Values indicate Mean ± SD or Median (interquartile 
range). *p < 0.05 vs. Baseline.
CKD CKD + BßGlucans
p value(n = 13) (n = 13)
Serum Creatinine (mg/dL) 1.0 ± 0.2 0.8 ± 0.2 0.03
BUN (mg/dL) 52.9 ± 9.6 44.3 ± 7.2 0.02
Phosphaturia (nmol/24 hours) 1.9 ± 0.5 2.3 ± 0.6 0.15
Proteinuria (mg/24 hours) 101.1 ± 80.0 21.4 ± 32.1 0.04
α-Klotho (IOD/Area) 1,477.2 ± 459.7 3,197.0 ± 1839.4 0.02
Lymphocyte infiltration (% Area) 2.2 ± 2.4 1.0 ± 0.7 0.04
Table 2. Biomarkers of renal dysfunction in rat CKD. Values indicate Mean ± SD.
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Protocol 3 examined the impact of uremia-driven inflammation on VSMC phenotype. The exposure of A7r5 
to uremic serum from hyperphosphatemic rats for 16 hours significantly increased TNFα and ADAM17 gene 
expression. However, the almost 2-fold increase in nSMase2 gene expression was not statistically significant 
(Fig. 6a–c). By contrast, exposure of A7r5 cells to uremic serum + Bßglucans maintained the mRNA of the three 
markers of inflammation at levels similar to those in the cells exposed to control serum, which was not affected 
by exposure to Bßglucans (Fig. 6a–c).
In A7r5 cells exposed to normal serum, Bßglucans had no effect on basal levels of the osteogenic markers. 
Instead, the uremic serum only increased Runx2 gene expression with no significant changes in either α-actin 
or Osterix (Fig. 6d–f). However, the addition of 100 µg/mL of Bßglucans to the uremic serum prevented the 
increases in Runx2 gene expression maintaining its levels at basal values.
In vitro studies. Direct anti-calcifying and anti-nSMase2 actions by BßGlucans. In Protocol 4, 
A7r5 cells were exposed exclusively to calcifying media (CM: 2 mM Ca; 3 mM P) during 4 days, which increased 
Figure 2. Renoprotection by dietary Bßglucans in hyperphosphatemic rat CKD. (a) Representative 
immunohistochemical images of renal ADAM17 from 5/6NX rats fed a high P diet with none (CKD; n = 13) 
or 2 mg of Bßglucans/g diet (CKD + Bßglucans; n = 13) during 4 weeks (Inset bars indicate relative scale); (b) 
Quantification of immunostaining. Bars and error bars represent mean ± SD of Histoscores values for all rats 
in both dietary groups; (c) Box plot analysis of nSMase2 gene expression in kidneys from rats described in (a). 
**p < 0.01 and ***p < 0.001 vs. CKD.
CKD CKD + BßGlucans
p value(n = 13) (n = 13)
Calcium (mg/dL) 9.8 ± 0.5 9.2 ± 0.8 0.19
Phosphate (mg/dL) 8.1 ± 2.6 7.7 ± 2.2 0.66
PTH (pg/mL) 3107 ± 2152 2044 ± 1127 0.14
25-hydroxyvitamin D (ng/mL) 29.4 ± 8.7 27.9 ± 6.5 0.63
FGF23 (ng/mL) 10.9 ± 5.6 12.5 ± 6.5 0.58
Bone alkaline phosphatase (U/mL) 42.1 (33.3–70.2) 28.1 (16.9–74.0) 0.28
(1,3)-β-D-glucan (pg/mL) Undetectable Undetetectable —
Table 3. Serum biomarkers of bone and mineral metabolism in rat CKD. Values indicate Mean ± SD or Median 
(interquartile range).
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Figure 3. Anti-inflammatory vascular protection by dietary BßGlucans. (a) Representative immunostaining 
for ADAM17 (Inset bars indicate relative scale) in thoracic aortas from 5/6NX rats fed a high P diet with none 
(CKD; n = 13) or 2 mg of Bßglucans/g diet (CKD + Bßglucans; n = 13) during 4 weeks. (b) Quantification of 
aortic ADAM17 immunostaining. Box plots represent median (interquartile range) of OD/Area values for all 
rats in both dietary groups. (c) Aortic ADAM17 and TNFα gene expression; (d) Aortic nSMase2 mRNA (white 
bars; CKD n = 9; CKD + Bßglucans n = 7) and activity (black bars; CKD n = 13; CKD + Barley n = 11). R.U.: 
Relative units. Bars and error bars represent mean ± SD; *p < 0.05 vs. CKD.
Figure 4. Anti-calcifying protection by dietary BßGlucans. (a) Representative calcium deposition measured 
by Von Kossa (black) staining (Inset bars indicate relative scale) in thoracic aortas from 5/6NX rats fed a high 
P diet with none (CKD; n = 13) or 2 mg of Bßglucans/g diet (CKD + Bßglucans; n = 13) during 4 weeks. (b) 
Quantification of calcium deposition in thoracic aortas described in (a); boxplot analysis of changes in calcium 
content, *p < 0.05 vs. CKD.
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calcium deposition by 13-fold. The addition of BßGlucans to the CM markedly attenuated (by 72%) the increases 
in calcium deposition induced by the CM (Fig. 7a), prevented the decrease in α-actin and the increases in osteo-
genic Osterix and Runx2 mRNA levels (Fig. 7b).
Similar results were found in ex vivo experiments culturing aortic rings from normal rats under the same 
calcifying conditions used in A7r5 (data not shown).
In addition, in A7r5 cells exposed to CM, the activity of nSMase2 increased by 3-fold, an induction totally 
prevented by adding 100 µg/mL of BßGlucans to the CM (Fig. 7c).
These direct anti-calcifying actions of BßGlucans extracts occurred in cells with undetectable mRNA levels 
of the β-glucan receptor Dectin 1 (not shown) and involved β-glucan internalization into A7r5 cells, as demon-
strated by significant increases in intracellular BßGlucans levels from undetectable in cells exposed to the Non 
CM or CM alone to 2.3 ng/well (p < 0.01) in cells exposed to the CM + Bßglucans.
Discussion
This work presents unprecedented properties of dietary Bβglucans of high translational relevance to attenuate 
systemic inflammation in health, as well as the progression of renal and vascular damage predisposing to VC in 
hyperphosphatemic rat CKD. These Bβglucans actions extend beyond the inhibition of leukocyte superoxide pro-
duction and of STING/interferon-like pro-aging/proinflammatory signals that precede any elevation of systemic 
inflammatory markers above normal levels, and involve a marked suppression of leukocyte, renal and vascular 
ADAM17 and nSMase2.
Bßglucans control of systemic inflammation in health. In healthy adults, the daily intake of 3 g of 
Bβglucans, recommended by the FDA to lower serum cholesterol21,22 could rapidly and efficaciously suppress 
systemic inflammation, a recognized inducer of VC. Indeed, dietary Bβglucans markedly reduced circulating 
leukocyte superoxide production (50%) as well as leukocyte ADAM17 and nSMase2 gene expression (60%) after a 
week intake, despite unchanged serum levels of CRP, TNFα and several other inflammatory cytokines, all within 
the normal range, and undetectable serum β-glucans concentrations. Despite the small size of this population of 
adults with normal renal function, Bβglucans rapid inhibition of these two pro-inflammatory genes in circulating 
leukocytes supports their potential to prevent/attenuate ADAM17-driven multi-organ injury and mortality rates9, 
and also nSMase2-driven age-enhanced inflammation regardless of serum TNFα10 and the propensity for ather-
omatous lesions17, as conclusively demonstrated in experimental models of ADAM17 or nSMase2 gene ablation.
Significantly, by week 4, dietary Bβglucans exerted a stronger (80 to 90%) inhibition of both ADAM17 
and nSMase2 gene expression, and also markedly inhibited leukocyte TNFα mRNA levels, despite no further 
reductions of either of their inducers: superoxide production and serum TNFα. Thus, dietary Bβglucans inhi-
bition of leukocyte ADAM17, nSMase2 and TNFα gene expression involved mechanisms other than suppress-
ing oxidative stress induction of ADAM178,14 and nSMase2 gene expression10,23, or TNFα-self up-regulation13. 
Significantly, among the inflammatory cytokines measured, dietary BßGlucans markedly reduced only circulat-
ing γ-interferon levels by week 4. This finding led us to evaluate whether dietary BßGlucans could also attenuate 
interferon-likepro-senescence/pro-inflammatory responses initiated by activation of the cGAS/STING path-
way20,24,25. We found that serum γ-interferon not only strongly correlated with leukocyte STING mRNA but, more 
significantly, dietary BßGlucans caused a 90% reduction of leukocyte STING mRNA by week 4. Thus, leukocyte 
STING emerged as a novel sensitive biomarker of leukocyte pro-aging/pro-inflammatory features, as its reduc-
tions by dietary BßGlucans precede any elevations above normal in circulating levels of inflammatory cytokines, 
including γ-interferon. Furthermore, the strong correlation between leukocyte STING and nSMase2 mRNA lev-
els suggests that dietary BßGlucans´progressive and simultaneous suppression of leukocyte STING and nSMase2 
gene expression could contribute to attenuate the age-enhanced inflammation attributed to increases in nSMase2 
in health. Indeed, enhanced nSMase2 release of exosomes from leukocytes carrying a cGAS/STING-driven senes-
cence/inflammation-associated secretory phenotype would propagate these signals to healthy neighboring cells26. 
Even though the accuracy of these early biomarkers of the anti-aging, anti-inflammatory actions of BßGlucans 
was only identified in the 5 normal individuals who completed the 4 weeks of BßGlucans intake, the strength of 
the leukocyte STING/nSMase2 association (r2 = 0.65) provides a solid base for early antinflammatory actions that 
need to be further corroborated in larger cohorts and long-term studies.
Bßglucans renal and vascular protection in hyperphosphatemic CKD. In hyperphosphatemic rat 
CKD, a daily intake of 40 mg of Bβglucans, as barley flour, effectively reduced inflammation-driven renal injury 
by targeting renal elevations in ADAM17, an enzyme induced by CKD of all etiologies12 and also by TNFα14 
and oxidative stress8, despite undetectable serum β-glucan levels. The higher renal ADAM17 in uremic controls 
CKD CKD + BßGlucans p value
α-actin mRNA (R.U.)
0.97 (0.69–1.45) 1.20 (0.37–1.41)
0.696
N = 12 N = 9
Runx2 mRNA (R.U.)
1.67 (1.11–2.58) 1.51 (0.9–1.91)
0.481
N = 10 N = 11
Osterix mRNA (R.U.)
0.72 (0.47–1.13) 0.53 (0.47–0.73)
0.374
N = 12 N = 9
Table 4. Biomarkers of vascular osteogenic differentiation in rat CKD. Values indicate Median (interquartile range).
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Figure 5. Bßglucans attenuate the vascular smooth muscle cell inflammation and osteogenic differentiation 
induced by LPS. Gene expression of nSMase2 (a), TNFα (b), ADAM17 (c), α-actin (d), Runx2 (e) and Osterix 
(f) in A7r5 cells exposed to control medium (CONTROL), 100 μg/mL of Bßglucans (β-GL), 5 µg/mL of LPS 
(LPS) or the combination of 100 μg/mL of Bßglucans and 5 µg/mL of LPS (LPS + ß-GL) for 16 hours. Bars 
and error bars represent mean ± SD from three independent experiments, each performed in triplicate per 
experimental condition. R.U.: relative units. **p < 0.01 and ***p < 0.001 vs. Control, #p < 0.05 and ###p < 0.001 
vs. LPS.
Figure 6. Bßglucans attenuate vascular smooth muscle cell inflammation and osteogenic differentiation 
induced by uremic conditions. Gene expression of nSMase2 (a), TNFα (b), ADAM17 (c), α-actin (d), Runx2 (e) 
and Osterix (f) in A7r5 cells exposed to serum from rats with normal renal function (Control), with or without 
100 μg/mL of Bßglucans (β-GL), or exposed to serum from rats with 14 weeks of uremia fed a high phosphorus 
diet (Uremic) with or without 100 μg/mL of Bßglucans for 16 hours. Bars and error bars represent mean ± SD 
from three independent experiments, each performed in triplicate per experimental condition. R.U.: relative 
units. **p < 0.01 and ***p < 0.001 vs. Control, ##p < 0.01, ###p < 0.001 and ####p < 0.0001 vs. Uremic.
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is sufficient to explain their increased inflammatory cell infiltration and 24 h proteinuria, as demonstrated by 
Lautrette and co-workers12. In turn, the higher proteinuria of uremic controls could mediate the faster decline in 
GFR, as recently reported27, and corroborated herein by the higher serum creatinine and BUN in the CKD group.
Dietary Bβglucans also reduced renal nSMase2 gene expression, which could extend the renoprotective ben-
efits of this nutritional strategy to hypertensive individuals28, by counteracting angiotensin II-driven-increases 
in renal nSMase2 or to diabetic nephropathy, by reducing the release to the urine of megalin loaded exosomes29.
Bβglucans simultaneous attenuation of CKD progression and renal inflammatory cell infiltration, the 
two most potent down-regulators of renal α-klotho content5,30, resulted in a higher renal α-klotho in the 
CKD + Bβglucans group. However, phosphaturia was similar between dietary groups, which suggested that the 
higher renal klotho was insufficient to ameliorate kidney resistance to FGF23 and, consequently, the deleterious 
renal impact of phosphate retention.
Figure 7. Bßglucans attenuate calcium deposition by inhibiting vascular smooth muscle cell osteogenic 
differentiation and nSMase2 activity. (a) Calcium deposition in A7r5 cells exposed to non-calcifying media 
(Non CM: 1 mM Ca; 1 mM P) or calcifying media (CM: 2 mM Ca; 3 mM P) with 0 or 100 μg/mL of Bßglucans 
(CM + β-GL) during 4 days. (b) Gene expression of α–actin (white bars), osterix (black bars) and Runx2 (gray 
bars) in A7r5 cells treated as described. (c) nSMase2 activity in A7r5 cells treated as described. Bars and error 
bars represent mean ± SD from three independent experiments performed in triplicate per experimental 
condition. R.U.: relative units. *p < 0.05 and **p < 0.01 vs. Non CM, #p < 0.05 and ##p < 0.01 vs. CM.
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In the inflamed aortas from these uremic rats, TNFα mRNA levels correlated directly with ADAM17 mRNA, 
partly reflecting the expected TNFα induction of ADAM179 and of its own gene13,14, and also with nSMase2 
mRNA levels and activity. Dietary Bβglucans suppressed by 80% the self-perpetuating aortic ADAM17/
TNFα-inflammatory loop9 and prevented the 3-fold elevations in nSMase2 reported to prompt pro-calcifying 
exosome release16, thereby reducing aortic calcium deposition in the CKD + Bβglucans group by 8-fold com-
pared to that in uremic controls. Interestingly, the higher calcium in uremic controls was unrelated to changes 
in the expression of markers of osteogenic differentiation and strongly correlated only with increased nSMase2. 
Thus, our aortic findings support the evidence that exosomes released by nSMase2 are the earliest calcified par-
ticles preceding overt calcification31, and also, that there are differential increases in vascular nSMase2 release of 
calcified and noncalcified exosomes causing heterogeneous calcium deposition at sites of early calcification31,32. 
Furthermore, Von Kossa staining was positive only in 36% of the aortas from uremic controls supporting that 
overt calcification is a late event in the course of CKD. Significantly, dietary Bßglucans fully prevented overt cal-
cification, as none of the aortas in the barley group was Von Kossa positive despite no amelioration of systemic 
calcium and phosphate homeostasis.
Importantly, a Bβglucans intake effective at reducing aortic nSMase2 gene expression and activity had no 
adverse impact on bone mineralization, as estimated by serum bone specific alkaline phosphatase levels. This 
is an important translational consideration to design therapeutic anti-nSMase2 strategies in CKD because the 
nSMase2 null mouse presents severe bone and dental mineralization defects33,34.
Mechanisms for Bßglucans´ actions. An intriguing aspect of Bβglucans potent anti-inflammatory, 
anti-ADAM17, anti-nSMase2, renal and vascular protective actions in vivo, is that they occurred with undetecta-
ble serum βglucans levels. Indeed, part of these actions may not require intestinal Bβglucans absorption because 
oral Bβglucans induce a saccharolytic shift in the microbiota that augments serum levels of anti-inflammatory 
short chain fatty acids, and also reduces circulating levels of p-cresyl-sulfate35, a uremic toxin promoting renal 
and cardiovascular injury36,37.
However, our studies in vitro in murine monocytes and VSMC exposed to commercially available Bβglucans 
extracts (95% purity) demonstrated direct anti-inflammatory, anti-calcifying actions that support the pharma-
cokinetics of dietary Bβglucans absorbed in the gut38–40. Specifically, in murine monocytes, we first identified that 
a dose of 100 µg/mL of Bβglucans extracts was necessary to prevent the 2-fold increases in mitochondrial super-
oxide production induced by a 16 h exposure to an LPS challenge (5 µg/mL). Significantly, this anti-inflammatory 
dose of Bβglucans also reduced by 50% the superoxide production in unstimulated monocytes, thus reproducing 
the 50% inhibition exerted in normal subjects after a week, or a month, of a daily intake of 3 g of Bβglucans.
Furthermore, the exposure of A7r5 cells to LPS (5 µg/mL for 16 h) corroborated that severe inflamma-
tion rapidly induced a switch to an osteogenic phenotype, as the increases in the mRNA levels for ADAM17, 
nSMase2 and TNFα were associated to decreases in α-actin and increases in the osteogenic markers Runx2 and 
osterix. Importantly, the simultaneous exposure of A7r5 cells to LPS and the effective anti-inflammatory dose 
of Bβglucans in immune cells, fully prevented LPS-induced inflammatory and osteogenic phenotypic changes 
without affecting VSMC baseline phenotype.
A7r5 cells also responded rapidly to uremic stimuli (serum from hyperphosphatemic rat CKD for 16 h) with 
significant elevations in ADAM17, TNFα and Runx2, but without significant increases in nSMase2 and osterix or 
decreases in α-actin. Nonetheless, Bβglucans fully prevented all uremia-induced changes, thus maintaining base-
line levels of all of these inflammatory/osteogenic markers. These findings support that a threshold for inflam-
matory or uremic stimuli is necessary to increase nSMase2 and osteogenic markers to levels resulting in overt 
calcification.
In VSMC exposed exclusively to prolonged (4 days) high Ca/high P conditions, Bβglucans extracts decreased 
by 60% nSMase2 gene expression in the absence of any inflammatory or uremic stimuli, through a process involv-
ing β1,3-glucan internalization into VSMC that is Dectin1-independent, as A7r5 cells showed undetectable 
Dectin1 mRNA levels. Several β-glucans receptors expressed in VSMC (Complement Receptor 3 or TLR2/6)41,42 
could mediate Bβglucans actions in A7r5 cells.
The internalization of (1,3)β-D-glucans into A7r5 cells exposed to Bβglucans extracts may also occur in 
other Bβglucans target cells, which could explain in part the systemic, renal and vascular anti-inflammatory/
anti-nSMase2 actions of dietary Bβglucans in healthy adults and in hyperphosphatemic rat CKD despite unde-
tectable serum levels. Indeed, there is evidence that soluble β1,3-glucose polymers, generated from oat and barley 
grains by the highly predominant β1,3-β1,4-glucanase in human gut bacteria43, are internalized and further pro-
cessed by intestinal epithelial and immune cells to shorter β1,3-glucans. In turn, the shorter β1,3-glucans released 
to the circulation39 can be re-internalized into immune cells reducing serum levels while enhancing leukocyte 
systemic anti-oxidant/anti-inflammatory capacity41,44, as demonstrated herein in healthy adults.
Barley is the least expensive cereal grain. Therefore, dietary Bβglucans health benefits could reach the poorest 
populations of CKD patients and of healthy adults with systemic pro-aging or inflammatory problems and, there-
fore, at a higher risk for renal and vascular injury.
Prospective clinical trials are mandatory to evaluate the sensitivity and accuracy of leukocyte ADAM17, 
nSMase2 or TNFα mRNA and STING levels to personalize dietary Bβglucans interventions for efficacious sys-
temic, renal and vascular protection in the general population and to attenuate CKD progression and the initia-
tion of medial calcium deposition in human CKD.
Material and Methods
Ethics statements. Approval for the human study was obtained from the Institutional Review Board 
(Comité de Ética en Investigación Clínica del Hospital Universitario Central de Asturias), in compliance with 
the Declaration of Helsinki. All participants gave a written informed consent prior to their inclusion in the study.
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Approval for the animal study was obtained from the Ethics Committee for Animal Experimentation at Lleida 
University in compliance with current international legislation for animal research.
All methods in the experimental protocols described below were carried out following the regulations for 
biomedical research of the University of Lleida and the University of Oviedo.
Human study. Ten volunteers (2 men, 8 women, age 20 to 60 y.o.), with normal renal function ingested 
daily during 4 weeks barley bread, manufactured with flour from barley grains selected for their high (1-3)
(1-4)-β-D-glucans content (8%), to provide 3 g of BßGlucans (produced at Food Science and Technology 
Department, Lleida University). Blood (5 mL) was drawn at baseline and at week 1 and 4 to obtain plasma and 
circulating leukocytes (after red cell lysis). As systemic inflammation biomarkers, we measured leukocyte mito-
chondrial superoxide production by flow cytometry in freshly isolated leukocytes. In the five volunteers (1 man, 
4 women) that complied with the daily intake for one-month, we also quantified the mRNA levels of TNFα, 
ADAM17, nSMase2 and STING, as described in the in vitro studies. Serum levels of (1, 3)β-Dglucans, choles-
terol, glycemia, markers of renal function, calcium and phosphate homeostasis, and systemic inflammation were 
measured as specified in blood chemistries. The reason to abandon the study was the omission of the daily intake 
more than twice per week.
Animal study. Five-sixth nephrectomized (NX) female Sprague-Dawley rats (200–225 g) were fed during 4 
weeks a high phosphate diet (HPD: 0.9% P; 0.6% calcium, Ca; Altromin) containing either 0 (CKD: n = 13) or 
2 mg of BßGlucans/g diet (CKD + BßGlucans) from the barley flour described above, with no changes in dietary 
protein, P, carbohydrate or lipid content. The modified Megazyme method quantified final β-D-glucan content 
in the diet45.
In vitro studies. 
 I. BßGlucans anti-inflammatory actions were examined in the murine monocyte cell line Raw 264.7 and in 
the rat aortic VSMC line A7r5.
Protocol 1: Rested Raw264.7, synchronized at G0 by exposure to FBS-free DMEM medium for 6 h, were 
treated for 16 hours with 5 μg/mL LPS from Escherichia coli 0111:B4 (L4391, Sigma-Aldrich), 100 μg/mL of 
barley (1–3)(1–4)-β-D-glucans (G6513, Sigma-Aldrich; 95% purity) or both.
Protocol 2: A7r5 cells were exposed to 5 μg/mL LPS, 100 μg/mL of barley (1–3)(1–4)-β-D-glucans or both 
in DMEM + 1% foetal bovine serum (FBS) for 16 hours.
Protocol 3: To test uremia-driven inflammatory stimuli, A7r5 cells were exposed to either control serum 
(a pool from rats with normal renal function fed a normal P diet; DMEM + 10% control serum), or to 
uremic serum (a pool from rats with uremia of 14 weeks fed a high phosphorus diet; DMEM + 10% uremic 
serum), with or without 100 μg/mL of Bßglucans for 16 hours.
 II. BβGlucans anti-calcifying actions were examined in A7r5 cells and in aortic rings (1–2 mm) from normal 
rats.
Protocol 4: Aortic rings were washed in cold PBS containing P/S and then placed in fibronectin pre-coated 
(100 µg/mL) 6-well plates (8 rings/well) with growing media. A7r5 and aortic rings were exposed during 4 days 
to either non-calcifying medium (Non CM: DMEM-F12 + 0.1%BSA, 1 mM Ca, 1 mM P) or to calcifying medium 
(CM: DMEM-F12 + 0.1% BSA, 2 mM Ca, 3 mM P) with 0 or 100 μg/mL of BßGlucans. A7r5 levels of the β-glucan 
receptor Dectin1 were examined by qPCR and intracellular levels of (1–3) β-D-glucans as indicated in blood 
chemistries.
Blood chemistries and proteinuria. Human biochemical parameters were measured at the Medicine 
Laboratory of the Hospital Universitario Central de Asturias using Cobas 8000 (Roche Diagnostics) Module 
c702, for most parameters, and Module e801 for PTH immunoassay.
For animal studies spectrophotometry and immunoassay (Cobas 8000, Roche Diagnostics) were used to 
measure serum levels of Ca, P, creatinine and 25-hydroxyvitaminD (25(OH)D). QuantiChromTM Urea Assay 
Kit measured Blood Urea Nitrogen (BUN, BioAssay System). ELISA Kits were used to measure rat intact 
PTH (Immutopics), rat fibroblast growth factor 23 (FGF23; EMD Millipore), rat bone alkaline phosphatase 
(Biosource), blood and urinary rat TNFα (Abcam plc, Cambridge, UK). Serum human TNFα was measured by 
bead-based multiplex assay (BiolegendPlex, Biolegend, Germany) analyzed in a FACS Canto II flow cytometer 
(BD Biosciences) equipped with a FACS Diva 6.5 software, following manufacturers´ protocols. Test strips meas-
ured urinary protein (SIEMENS MULTISTICK 10SG, Analyticon Biochemistry). The FungitelTM kit (Associates 
of Cape Code, Inc) measured serum, plasma and intracellular (1,3)β-D-glucans.
Histological analyses. Rat renal and aortic 5 µm-paraffin sections were deparaffinized and hydrated. Renal 
ADAM17 and CD45 (leukocyte infiltration) immunostainings were performed as in46 and renal α-klotho with 
kit-CTS008 (R&D System). For aortic ADAM17 immunofluorescence nuclei were counterstained with Hoechst. 
For renal ADAM17, sections were counterstained with hematoxylin-eosin. Each slide had its negative control (no 
primary antibody). Supplementary Table 1 lists primary antibodies and dilutions. Quantifications used ImageJ 
or Histoscores47.
Mitochondrial superoxide production. Circulating human leukocytes and cultured Raw 264.7 cells were 
washed with PBS, resuspended in 5 µM superoxide sensitive probe MitoSOXTM (Thermo-Fisher Scientific) in PBS 
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with either vehicle or the corresponding treatment for 10 min at 37 °C, protected from light and washed twice 
with PBS. A FACS CantoTMII flow cytometer (Becton Dickinson Bioscience) measured superoxide anion levels.
Von kossa staining. Deparaffinized, hydrated rat aorta sections were incubated in 5% silver nitrate before 
the revealing solution. Slides placed in 2% sodium thiosulfate were counterstained with nuclear fast red.
Total calcium measurements. A 20 mm segment of the abdominal rat aorta proximal to the iliac bifurca-
tion was first grinded in liquid nitrogen and then decalcified with 0.6 N HCl. A7r5 cells, washed thrice with PBS, 
were decalcified with 0.6 N HCl.
Samples were shaken gently at 4 °C for 24 h. Upon centrifugation, O-cresolphthalein-complexone measured 
total calcium in supernatants. Pellets were re-suspended in lysis buffer (0.1 N NaOH, 0.1% SDS) for protein 
extraction and quantification (Lowry method, Bio-Rad).
For rat aortic rings, total calcium was measured as above in cell pellets from RNA extraction (below) and 
expressed as µg calcium/µg RNA.
Sphingomyelinase2 activity. The Amplex Red Sphingomyelinase assay kit (Molecular Probes, Invitrogen) 
was used in aorta sections and in A7r5 whole cell extracts.
Quantitative PCR. Total tissue or cell RNA, extracted with TRI reagent (Sigma-Aldrich), was reversed tran-
scribed with a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative-real time PCR 
(qPCR) reactions used the Stratagene Mx3005P QPCR System (Agilent Technologies), Fast Start Universal Probe 
Master (Roche), pre-developed assays (Thermo-Fisher Scientific) and ΔΔCt quantification48.
Statistical analysis. T tests, ANOVA or Kruskal-Wallis with Bonferroni post-hoc test examined statistical 
differences between groups. Results are expressed as mean ± SD unless otherwise stated. Statistical analyses used 
GraphPad Prism, SPSS 17.0 for Windows or R.
Data availability
No datasets were generated or analyzed during the current study.
Received: 9 September 2019; Accepted: 6 November 2019;
Published: xx xx xxxx
References
 1. Vervloet, M. & Cozzolino, M. Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int 91, 808–817 
(2017).
 2. Slatopolsky, E., Brown, A. & Dusso, A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 
37, S54–57 (2001).
 3. Paloian, N. J. & Giachelli, C. M. A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol 307, F891–900 
(2014).
 4. Navarro-Gonzalez, J. F., Mora-Fernandez, C., Muros, M., Herrera, H. & Garcia, J. Mineral metabolism and inflammation in chronic 
kidney disease patients: a cross-sectional study. Clin J Am Soc Nephrol 4, 1646–1654 (2009).
 5. Izquierdo, M. C. et al. Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant 27(Suppl 4), 
iv6–10 (2012).
 6. Massy, Z. A., Stenvinkel, P. & Drueke, T. B. The role of oxidative stress in chronic kidney disease. Semin Dial 22, 405–408 (2009).
 7. Zhao, M. M. et al. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced 
vascular calcification in vitro and in vivo. Kidney Int 79, 1071–1079 (2011).
 8. Brill, A. et al. Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent 
fashion. Cardiovasc Res 84, 137–144 (2009).
 9. Gooz, M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 45, 146–169 (2010).
 10. Rutkute, K., Asmis, R. H. & Nikolova-Karakashian, M. N. Regulation of neutral sphingomyelinase-2 by GSH: a new insight to the 
role of oxidative stress in aging-associated inflammation. Journal of lipid research 48, 2443–2452 (2007).
 11. Melenhorst, W. B. et al. ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability? Am J Physiol 
Renal Physiol 297, F781–790 (2009).
 12. Lautrette, A. et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 11, 
867–874 (2005).
 13. Tabibzadeh, S., Satyaswaroop, P. G., von Wolff, M. & Strowitzki, T. Regulation of TNF-alpha mRNA expression in endometrial cells 
by TNF-alpha and by oestrogen withdrawal. Mol Hum Reprod 5, 1141–1149 (1999).
 14. Charbonneau, M. et al. Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor 
necrosis factor-alpha converting enzyme/ADAM17 expression by synovial cells. J Biol Chem 282, 33714–33724 (2007).
 15. Horiuchi, K. et al. Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents 
lethality from endotoxin shock. J Immunol 179, 2686–2689 (2007).
 16. Kapustin, A. N. et al. Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ Res 116, 1312–1323 
(2015).
 17. Lallemand, T. et al. nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and 
Atherosclerosis in Apoe(−/−) Mice. Arterioscler Thromb Vasc Biol 38, 1479–1492 (2018).
 18. Habbous, S. et al. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating 
hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 32, 
111–125 (2017).
 19. Sandvik, A. et al. Oral and systemic administration of beta-glucan protects against lipopolysaccharide-induced shock and organ 
injury in rats. Clin Exp Immunol 148, 168–177 (2007).
 20. Kreienkamp, R. et al. A Cell-Intrinsic Interferon-like Response Links Replication Stress to Cellular Aging Caused by Progerin. Cell 
Rep 22, 2006–2015 (2018).
 21. Liu, S. et al. Whole-grain consumption and risk of coronary heart disease: results from the Nurses’ Health Study. Am J Clin Nutr 70, 
412–419 (1999).
13Scientific RepoRtS |         (2019) 9:17810  | https://doi.org/10.1038/s41598-019-54306-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
 22. Karmally, W. et al. Cholesterol-lowering benefits of oat-containing cereal in Hispanic americans. J Am Diet Assoc 105, 967–970 
(2005).
 23. Liu, B. & Hannun, Y. A. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 272, 
16281–16287 (1997).
 24. Cai, X., Chiu, Y. H. & Chen, Z. J. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Molecular cell 54, 
289–296 (2014).
 25. Yang, H., Wang, H., Ren, J., Chen, Q. & Chen, Z. J. cGAS is essential for cellular senescence. Proc Natl Acad Sci USA 114, 
E4612–e4620 (2017).
 26. Torralba, D. et al. Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven 
contacts. Nat Commun 9, 2658 (2018).
 27. Melsom, T. et al. Mild Albuminuria Is a Risk Factor for Faster GFR Decline in the Nondiabetic Population. Kidney Int Rep 3, 
817–824 (2018).
 28. Bautista-Perez, R. et al. Involvement of neutral sphingomyelinase in the angiotensin II signaling pathway. Am J Physiol Renal Physiol 
308, F1178–1187 (2015).
 29. De, S. et al. Exocytosis-Mediated Urinary Full-Length Megalin Excretion Is Linked With the Pathogenesis of Diabetic Nephropathy. 
Diabetes 66, 1391–1404 (2017).
 30. Hu, M. C. et al. Renal Production, Uptake, and Handling of Circulating alphaKlotho. J Am Soc Nephrol 27, 79–90 (2016).
 31. Kapustin, A. N. et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance 
mineralization. Circ Res 109, e1–12 (2011).
 32. Shroff, R. C. et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 
118, 1748–1757 (2008).
 33. Khavandgar, Z. et al. A cell-autonomous requirement for neutral sphingomyelinase 2 in bone mineralization. J Cell Biol 194, 
277–289 (2011).
 34. Aubin, I. et al. A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and 
dentinogenesis imperfecta in the mouse. Nat Genet 37, 803–805 (2005).
 35. Cosola, C. et al. Beta-Glucans Supplementation Associates with Reduction in P-Cresyl Sulfate Levels and Improved Endothelial 
Vascular Reactivity in Healthy Individuals. PLoS One 12, e0169635 (2017).
 36. Ito, S. & Yoshida, M. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Toxins 
(Basel) 6, 665–678 (2014).
 37. Lin, C. J., Wu, V., Wu, P. C. & Wu, C. J. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with 
Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure. PLoS One 10, e0132589 (2015).
 38. Iraz, M., Bilgic, S., Samdanci, E., Ozerol, E. & Tanbek, K. Preventive and early therapeutic effects of beta-glucan on the bleomycin-
induced lung fibrosis in rats. Eur Rev Med Pharmacol Sci 19, 1505–1516 (2015).
 39. Hong, F. et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal 
antibodies in murine tumor models. J Immunol 173, 797–806 (2004).
 40. Rice, P. J. et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. 
J Pharmacol Exp Ther 314, 1079–1086 (2005).
 41. Chan, G. C., Chan, W. K. & Sze, D. M. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol 2, 25 (2009).
 42. Han, Y. et al. Role of complement 3a in the synthetic phenotype and angiotensin II-production in vascular smooth muscle cells from 
spontaneously hypertensive rats. American journal of hypertension 25, 284–289 (2012).
 43. Tamura, K. et al. Molecular Mechanism by which Prominent Human Gut Bacteroidetes Utilize Mixed-Linkage Beta-Glucans, Major 
Health-Promoting Cereal Polysaccharides. Cell Rep 21, 417–430 (2017).
 44. Novak, M. & Vetvicka, V. Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action. J 
Immunotoxicol 5, 47–57 (2008).
 45. Motilva, M. J. et al. Adaptation of the standard enzymatic protocol (Megazyme method) to microplaque format for β-(1,3)
(1,4)-d-glucan determination in cereal based samples with a wide range of β-glucan content. Journal of Cereal Science 59, 224–227 
(2014).
 46. Arcidiacono, M. V., Yang, J., Fernandez, E. & Dusso, A. The induction of C/EBPbeta contributes to vitamin D inhibition of ADAM17 
expression and parathyroid hyperplasia in kidney disease. Nephrol Dial Transplant 30, 423–433 (2015).
 47. Arcidiacono, M. V., Yang, J., Fernandez, E. & Dusso, A. Parathyroid-specific epidermal growth factor-receptor inactivation prevents 
uremia-induced parathyroid hyperplasia in mice. Nephrol Dial Transplant 30, 434–440 (2015).
 48. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta 
C(T)) Method. Methods 25, 402–408 (2001).
Acknowledgements
Authors thank Dr. Roxana Savin (Agrotechnio Research Center, Lleida University) for generating barley grain 
with high (8%) β-glucan content by multiplying lines selected for this trait (provided by Semillas Batlle, Spain) 
and for valuable suggestions for project design; Ana Martínez (IRB Lleida) for diet-chow preparation and Xenia 
Borràs (Food Technology Dept., Agrotecnio Research Center, Lleida University) for Barley bread preparation. 
A grant to A.S.D. and M.J.M. from IRBLleida and Agrotecnio Research collaborative projects from the Consell 
Social at Lleida University supported initial work, Instituto de Salud Carlos III and co-funded by European 
Union (ERDF/FEDER) (FIS PI11/00259, PI14/01452, PI17/02181), Plan de Ciencia, Tecnología e Innovación 
2013–2017 y 2018–2022 del Principado de Asturias (GRUPIN14-028, IDI-2018-000152), RedInRen from ISCIII 
(ISCIII-RETIC REDINREN RD16/0009). Investigator support included: NC-L by GRUPIN14-028 and IDI-2018-
000152, LM-A by GRUPIN14-028, SP by FICYT; MVA and PV by Educational Grant 2 A/2015 from ERA-EDTA 
CKD-MBD Working Group; PV and AC by ERA-EDTA fellowships 2011 and 2012; JR-C by MINECO (“Juan 
de la Cierva” program, FJCI-2015-23849); A.S.D. by Asociación Investigación de Fisiología Aplicada. A.S.D. and 
M.J.M. are members of the Campus Iberus (Ebro Valley Campus of International Excellence).
Author contributions
M.J.M., C.R., J.B.C.-A. and A.S.D. designed the study; M.V.A., N.C.-L., S.P., A.L.C.-G., P.V., C.U., A.C., C.Q.-C., 
L.M.-A., J.R.-C. and AS.D. performed experiments and analyzed results; M.V.A., N.C.-L. made figures; M.V.A., 
N.C.-L., S.P., C.M.-S., M.J.M., C.R., J.B.C.-A. and A.S.D. drafted and reviewed the manuscript. All authors 
approved the final version.
1 4Scientific RepoRtS |         (2019) 9:17810  | https://doi.org/10.1038/s41598-019-54306-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-54306-8.
Correspondence and requests for materials should be addressed to A.S.D.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
